Cyclo Therapeutics, Inc.

CYTH
NASDAQ
Last Updated: 12/5/2022 9:00:03 PM
Price
1.9
Changes
-0.04
% Change
-2.06
Volume
122437
52 Week
High
5.15
52 Week
Low
0.91
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Cyclo Therapeutics, Inc. Company Details
Information is currently Not Available for Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc. Company Executive Details
  Ms. Lori McKenna Gorski
  Global Head of Patient Advocacy
  Mr. Russ Belden
  Acting Chief Commercial Officer
  Mr. Michael Eric Lisjak
  Chief Regulatory Officer & Senior Vice President of Bus. Devel.
  Dr. Caroline Hastings M.D.
  Global Principal Investigator of TransportNPC & Member of Scientific Advisory Board
  Mr. George L. Fails
  Executive Vice President and Operations Mang.

Cyclo Therapeutics, Inc. Latest News

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference


GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-


Published on: 2022-09-07 08:05:00

Impact on Symbol / Company: CYTH

View News

Cyclo Therapeutics to Present at the China NPC Association Meeting


GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the 2022 China Nieman Pick Medical Exchange & Sixth Patient Association being held August 13, 2022 in Xiamen,


Published on: 2022-08-08 08:05:00

Impact on Symbol / Company: CYTH

View News

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022


GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it will participate at the 30th Annual NNPDF Family Support & Medical Conference in conjunction with the INPDA Biennial Meeting being held July 28-31, 2022, in Orlando, FL. “Perspectives from


Published on: 2022-07-21 08:05:00

Impact on Symbol / Company: CYTH

View News

Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022


GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 in Boston, MA. During the session, Dr. Kjems w


Published on: 2022-07-11 08:05:00

Impact on Symbol / Company: CYTH

View News

Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation


GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Professor Caroline Hastings, MD will present at the 2022 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 23-24, 2022. Details of the presentation are as f


Published on: 2022-06-21 08:05:00

Impact on Symbol / Company: CYTH

View News

Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference


GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 PM ET. In addition to the presentation, ma


Published on: 2022-03-10 08:05:00

Impact on Symbol / Company: CYTH

View News

Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022


GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the poster presentation of its ongoing pivotal Phase 3 study, TransportNPC™ at the 18th Annual WORLDSymposium 2022, a leading medical and scientific conference for professionals working to advance und


Published on: 2022-02-08 08:05:00

Impact on Symbol / Company: CYTH

View News

Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference


GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 10:00 AM ET. As part of the virtual ev


Published on: 2022-01-20 08:05:00

Impact on Symbol / Company: CYTH

View News

Anti-Amyloid Drugs: The Failure Of Success


Anti-Amyloid Drugs: The Failure Of Success


Published on: 2022-01-01 07:04:04

Impact on Symbol / Company: CYTH

View News

Cyclo Therapeutics (CYTH) Stock: Why The Price Dropped Today


The stock price of Cyclo Therapeutics Inc (NASDAQ: CYTH) fell by over 15% pre-market today. This is why it happened.


Published on: 2021-11-17 06:38:55

Impact on Symbol / Company: CYTH

View News

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease


Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease


Published on: 2021-11-16 01:47:38

Impact on Symbol / Company: CYTH

View News

Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event


GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will participate in the Virtual Investor Roundtable Event on Tuesday, November 16,


Published on: 2021-11-10 08:05:00

Impact on Symbol / Company: CYTH

View News

Grow your Money

We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures

Services we Offer

We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others

Live Market Data

We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you